Frequent activation of the PI3K/mTOR pathway contributes to tumor growth and immune invasion; inhibition of this pathway has shown to transform the TME and sensitize uLMS to PD-1 blockade in preclinical models [26]. Here, MTOR is linked to neoplasm.